Abstract
The human concentrative nucleoside transporter, CNT3 (SLC28A3), plays an important role in mediating the cellular entry of a broad array of physiological nucleosides and synthetic anticancer nucleoside analog drugs. As a first step toward understanding the genetic basis for interindividual differences in the disposition and response to antileukemic nucleoside analogs, we examined the genetic and functional diversity of CNT3. In all, 56 variable sites in the exons and flanking intronic region of SLC28A3 were identified in a collection of 270 DNA samples from US populations (80 African-Americans, 80 European-Americans, 60 Asian-Americans, and 50 Mexican-Americans). Of the 16 coding region variants, 12 had not been previously reported. Also, 10 resulted in amino-acid changes and three of these had total allele frequencies of ≥1%. Nucleotide diversity (π) at nonsynonymous and synonymous sites was estimated to be 1.81 × 104 and 18.13 × 104, respectively, suggesting that SLC28A3 is under negative selection. All nonsynonymous variants, constructed by site-directed mutagenesis and expressed in Xenopus laevis oocytes, transported purine and pyrimidine model substrates, except for c. 1099G>A (p. Gly367Arg). This rare variant alters an evolutionarily conserved site in the putative substrate recognition domain of CNT3. The presence of three additional evolutionarily conserved glycine residues in the vicinity of p. Gly367Arg that are also conserved in human paralogs suggest that these glycine residues are critical in the function of the concentrative nucleoside transporter family. The genetic analysis and functional characterization of CNT3 variants suggest that this transporter does not tolerate nonsynonymous changes and is important for human fitness.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Baldwin SA, Mackey JR, Cass CE, Young JD . Nucleoside transporters: molecular biology and implications for therapeutic development. Mol Med Today 1999; 5: 216–224.
Ritzel MW, Ng AM, Yao SY, Graham K, Loewen SK, Smith KM et al. Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J Biol Chem 2001; 276: 2914–2927.
Mangravite LM, Badagnani I, Giacomini KM . Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney. Eur J Pharmacol 2003; 479: 269–281.
Pott C, Hiddemann W . Purine analogs in the treatment of chronic lymphocytic leukemia. Leukemia 1997; 11: S25–S28.
Robak T . The role of nucleoside analogues in the treatment of chronic lymphocytic leukemia–lessons learned from prospective randomized trials. Leuk Lymphoma 2002; 43: 537–548.
Molina-Arcas M, Bellosillo B, Casado FJ, Montserrat E, Gil J, Colomer D et al. Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. Blood 2003; 101: 2328–2334.
Gray JH, Mangravite LM, Owen RP, Urban TJ, Chan W, Carlson EJ et al. Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. Mol Pharmacol 2004; 65: 512–519.
Leabman MK, Huang CC, DeYoung J, Carlson EJ, Taylor TR, de la Cruz M et al. Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci USA 2003; 100: 5896–5901.
Stephens M, Smith NJ, Donnelly P . A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978–989.
Nebert DW . Proposal for an allele nomenclature system based on the evolutionary divergence of haplotypes. Hum Mutat 2002; 20: 463–472.
Grantham R . Amino acid difference formula to help explain protein evolution. Science 1974; 185: 862–864.
Wang J, Giacomini KM . Molecular determinants of substrate selectivity in Na+-dependent nucleoside transporters. J Biol Chem 1997; 272: 28845–28848.
Fay JC, Wyckoff GJ, Wu CI . Positive and negative selection on the human genome. Genetics 2001; 158: 1227–1234.
Gray JH, Owen RP, Giacomini KM . The concentrative nucleoside transporter family, SLC28. Pflugers Arch 2004; 447: 728–734.
Stephens JC, Schneider JA, Tanguay DA, Choi J, Acharya T, Stanley SE et al. Haplotype variation and linkage disequilibrium in 313 human genes. Science 2001; 293: 489–493.
Miller MP, Kumar S . Understanding human disease mutations through the use of interspecific genetic variation. Hum Mol Genet 2001; 10: 2319–2328.
Shu Y, Leabman MK, Feng B, Mangravite LM, Huang CC, Stryke D et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci USA 2003; 100: 5902–5907.
Vitkup D, Sander C, Church GM . The amino-acid mutational spectrum of human genetic disease. Genome Biol 2003; 4: R72.
Majewski J, Ott J . Amino acid substitutions in the human genome: evolutionary implications of single nucleotide polymorphisms. Gene 2003; 305: 167–173.
Wang Z, Moult J . SNPs, protein structure, and disease. Hum Mutat 2001; 17: 263–270.
Partridge AW, Therien AG, Deber CM . Polar mutations in membrane proteins as a biophysical basis for disease. Biopolymers 2002; 66: 350–358.
Russ WP, Engelman DM . The GxxxG motif: a framework for transmembrane helix–helix association. J Mol Biol 2000; 296: 911–919.
Osato DH, Huang CC, Kawamoto M, Johns SJ, Stryke D, Wang J et al. Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1. Pharmacogenetics 2003; 13: 297–301.
Leabman MK, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE et al. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 2002; 12: 395–405.
Toan SV, To KK, Leung GP, de Souza MO, Ward JL, Tse CM . Genomic organization and functional characterization of the human concentrative nucleoside transporter-3 isoform (hCNT3) expressed in mammalian cells. Pflugers Arch 2003; 447: 195–204.
Tajima F . Statistical method for testing the neutral mutation hypothesis by DNA polymorphism. Genetics 1989; 123: 585–595.
Hartl DL, Clark AG . Principles of Population Genetics, 3rd edn. Sunderland, MA: Sinauer Associates, 1997.
Zhang L, Schaner ME, Giacomini KM . Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther 1998; 286: 354–361.
Acknowledgements
This work was supported by the National Institute of Health (NIH) grants GM61390 and GM42230. IB was supported in part by a National Science Foundation Graduate Research Fellowship. The study was supported by the General Clinical Research Center at San Francisco General Hospital, funded by the National Center for Research Resources, National Institutes of Health (grant MO1-RR00083-42). We thank Jennifer Gray and Ryan Owen for their thoughtful advice and technical assistance.
Author information
Authors and Affiliations
Corresponding author
Additional information
DUALITY OF INTEREST
None declared.
Rights and permissions
About this article
Cite this article
Badagnani, I., Chan, W., Castro, R. et al. Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3). Pharmacogenomics J 5, 157–165 (2005). https://doi.org/10.1038/sj.tpj.6500303
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.tpj.6500303
Keywords
This article is cited by
-
Cladribine as a Potential Object of Nucleoside Transporter-Based Drug Interactions
Clinical Pharmacokinetics (2022)
-
Cell-surface SLC nucleoside transporters and purine levels modulate BRD4-dependent chromatin states
Nature Metabolism (2021)
-
Review of Transporter Substrate, Inhibitor, and Inducer Characteristics of Cladribine
Clinical Pharmacokinetics (2021)
-
Relationship between Azathioprine metabolites and therapeutic efficacy in Chinese patients with neuromyelitis optica spectrum disorders
BMC Neurology (2017)
-
Rosetta Broker for membrane protein structure prediction: concentrative nucleoside transporter 3 and corticotropin-releasing factor receptor 1 test cases
BMC Structural Biology (2017)